Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | KLF5 | Q13887 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.70 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.70 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.70 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.70 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.70 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.70 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.70 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydroouabain SCHEMBL12840814 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53NPC1RAB9ALMNA | |
| Dihydroouabain SCHEMBL30749160 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53NPC1RAB9ALMNA | |
| Dihydroouabain SCHEMBL29666955 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53NPC1RAB9ALMNA | |
| Ouabain SCHEMBL2524203 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53NPC1RAB9ALMNA | |
| Ouabain SCHEMBL22824877 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53NPC1RAB9ALMNA | |
| Ouabain SCHEMBL24444049 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53NPC1RAB9ALMNA | |
| Ouabain SCHEMBL21960068 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53NPC1RAB9ALMNA | |
| Ouabain SCHEMBL21960066 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53NPC1RAB9ALMNA | |
| Ouabain SCHEMBL15433 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53NPC1RAB9ALMNA | |
| Ouabain SCHEMBL12841141 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIV OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | US | claimed |
| EP-4536236-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | University of Utah Research Foundation (US) | 2025-04-16 | — | — | EP | claimed |
| CN-118421745-B | Enterococcus mundtii is produced application of dihydroouabain | 云南农业大学 | 2025-03-18 | — | — | CN | claimed |
| CN-118421745-A | Application of enterococcus mundtii in producing dihydroouabain | 云南农业大学 | 2024-08-02 | — | — | CN | claimed |
| EP-3654841-B1 | TARGETED OSMOTIC LYSIS OF MALIGNANT CANCER CELLS USING PULSED MAGNETIC FIELD GRADIENTS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2023239747-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-12-14 | — | — | WO | claimed |
| US-11654292-B2 | Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2023-05-23 | — | — | US | claimed |
| WO-2020247756-A1 | SMALL MOLECULES TO RELAX UTERINE SMOOTH MUSCLE CONTRACTIONS | FORCYTE BIOTECHNOLOGIES, INC. (US) | 2020-12-10 | — | — | WO | claimed |
| EP-3654841-A1 | TARGETED OSMOTIC LYSIS OF MALIGNANT CANCER CELLS USING PULSED MAGNETIC FIELD GRADIENTS | Board Of Supervisors Of Louisiana State University (US) | 2020-05-27 | — | — | EP | claimed |
| US-20200147405-A1 | TARGETED OSMOTIC LYSIS OF MALIGNANT CANCER CELLS USING PULSED MAGNETIC FIELD GRADIENTS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2020-05-14 | — | — | US | claimed |
| US-20120264810-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-10-18 | — | — | US | claimed |
| WO-2012082771-A1 | CARDIAC GLYCOSIDES FOR TREATING AUTOIMMUNE DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-06-21 | — | — | WO | claimed |
| WO-2011036557-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-03-31 | — | — | WO | claimed |
| EP-1163270-B1 | DIHYDROOUABAIN-LIKE FACTOR AND DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS | UNIV LOUISVILLE RES FOUND (US) | 2010-06-02 | — | — | EP | claimed |
| US-20080188425-A1 | Dihydroouabain-like factor and diagnostic & therapeutic compositions and methods | VALDES ROLAND | 2008-08-07 | — | — | US | claimed |
| US-20050123999-A1 | Dihydroouabain-like factor and diagnostic & therapeutic compositions and methods | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC., A KENTUCKY CORPORATION | 2005-06-09 | — | — | US | claimed |
| US-6835715-B1 | Mammalian dihydroouabain-like factor and therapeutic compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2004-12-28 | — | — | US | claimed |
| EP-1163270-A4 | DIHYDROOUABAIN-LIKE FACTOR AND DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS | UNIV LOUISVILLE RES FOUND (US) | 2004-05-19 | — | — | EP | claimed |
| EP-1163270-A1 | DIHYDROOUABAIN-LIKE FACTOR AND DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2000047624-A1 | DIHYDROOUABAIN-LIKE FACTOR AND DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2000-08-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | ATXN2, ATXN2L, ATP6V1B2 | SMN1; SMN2 49/4885TP53 1585/4885NPC1 2086/4885 |
| US-20050123999-A1 | Dihydroouabain-like factor and diagnostic & therapeutic compositions and methods | OLA1, PHF20, ATP5F1B | SMN1; SMN2 4519/4885TP53 3893/4885NPC1 1702/4885 |
| US-20080188425-A1 | Dihydroouabain-like factor and diagnostic & therapeutic compositions and methods | OLA1, PHF20, ATP5F1B | SMN1; SMN2 4519/4885TP53 3893/4885NPC1 1702/4885 |
| US-20120264810-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES | NPC1L1, ABCB4, NPC1 | SMN1; SMN2 1315/4885TP53 2548/4885NPC1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.